Colorectal cancer: Molecular staging models that charactrize risk and enhance prognosis

Cancer Genomics and Proteomics

Volumn 1, Issue 4, 2004, Pages 295-310

  Ahmed, Farid E ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Colorectal cancer; Gene expression index; Molecular staging models; Review

Indexed keywords

EID: 18844445435     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Ahmed FE: Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment. J Env Sci Health C21: 65-131, 2003.
2. Grizzle, WE, Manne U, Weiss H, Jhala N and Telley L: Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 and p27KIP1. Int J Cancer 97: 403-409, 2002.
3. Greene FL, Page DL, Fleming ID, Fritz AG, Blach CM, Haller DG and Morrow M: AJCC Cancer Staging Handbook, 6th edition. New York, Springer, 2002.
4. Chung DC: The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterol 119: 894-865, 2000.
5. Grizzle, WE, Manne U, Jhala NC and Weiss HL: Molecular characterization of colorectal neoplasia in translational research. Arch Pathol Lab Med 125: 91-98, 2001.
6. Pavlinkova G, Booth BJ, Batra SK and Colcher D: Radioimmunotherapy of human colon cancer xenografts among a dimeric single-chain FV antibody contruct. Clin Cancer Res 5: 2613-2619, 1999
7. Zwacka RM and Dunlop MG: Gene therapy for colon cancer. Hematol Oncol Clin North Am 5: 52-62, 1998.
8. Ahmed FE: Molecular markers for early cancer detection. J Env Sci Health C18: 75-126, 2000.
9. Duffy MJ: Carcinoembryonic antigen as a maker for colorectal cancer. Is it clinically useful? Clin Chem 47: 624-639, 2001.
10. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C and Topolcan O: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines. Eur J Cancer 39: 718-727, 2003.
11. Compton C, Fenoglio-Preiser CM, Pettigrew N and Fielding LP: American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88: 1739-1757, 2000.
12. Miura M, Ichikawa Y, Tanaka K, Kamiyama M, Hamaguchi Y, Ishikawa T, Yamaguchi S, Togo S, Ike H, Ooki S and Shimada H: Real-time PCR (TaqMan PCR) quantification of carcinoembryonic antigen (CEA) mRNA in the peripheral blood of colorectal cancer patients. Anticancer Res 23: 1271-1276, 2003.
13. Bustin SA, Siddiqi S, Ahmed S, Hands R and Dorudi S: Quantification of cytokeratin 20, carcinoembryonic antigen and guanylyl cyclase C mRNA levels in lymph nodes may not predict treatment failure in colorectal cancer patients. Int J Cancer 108: 412-417, 2004.
14. Hampton R, Walker M, Marshall J and Juhl L: Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells. Oncogene 21: 7817-7823, 2002.
15. Brandt-Rauf PW: Biomarkers of gene expression: growth factors and oncoproteins. Env Health Prespect 105 (Suppl 4): 807-816, 1997.
16. Andreyev HJ, Benamouzig R, Beranek M, Clarke P, Cunningham D, Norman AR, Gianelli W, de Goeij AF, Iacopetta BJ, Jullian E, Krolica K, Lee JQ, Wang ST, Lee N, Al-Mulla F, Muller O, Pauly M, Pricolo V, Russo A, Troungoo C, Urosevic N and Ward R: Mutant K-ras 2 in serum. Gut 52: 101-108, 2003.
17. Jervoise H, Andreyev N, Norman AR, Cunningham D, Oates JR and Clarke PA: Kristen ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. JNCI 90: 675-684, 1998.
18. Takahashi M, Fujita M, Furakawa Y, Hamamoto R, Shinokawa T, Miwa N, Ogawa M and Nakamura Y: Isolation of a novel human gene, APCDD1, as a direct target of beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis. Cancer Res 62: 5651-5656, 2002.
19. Jaiswal AS and Narayan S: p53-dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents. J Biol Chem 276: 18193-18199, 2001.
20. Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
21. Inomata M, Ochiai A and Akimoto S: Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res 56: 2213-2217, 1996.
22. Valentini AM, Pirrelli M, Renna L, Armentano R and Caruso ML: p53 and beta-catenin in colorectal cancer progression. Curr Pharmaceut Des 9: 639-652, 2003.
23. Iacopetta B: TP53 mutation in colorectal cancer. Human Mutat 21: 271-276, 2003.
24. Gonzalez-Aguilera JJ, Oliart S, Azcota M and Fernandez-Peratta M: Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colon cancer. Am J Clin Oncol 27: 39-45, 2004
25. Adams JM and Cory S: The bcl-2 protein family arbiters of cell survival. Science 281: 1322-1326, 1998.
26. Manne U, Weiss HL and Grizzle WE: Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinoma. Int J Cancer 89: 423-430, 2000.
27. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S and Grizzle WE: Prognostic significance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74: 346-358, 1997.
28. Jiang M and Miller J: Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Develop 17: 832-837, 2003.
29. La Casse EC, Baird S, Korneluk RG and Mackenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259, 1998.
30. Gilmore TK, Koedood M, Piffatt KA and White DW: Rel/NFkB proteins and cancer. Oncogene 13: 1367-1378, 1996.
31. Davidson LA, Lupton JR, Miskovsky E, Fields AP and Chapkin RS: Quantification of human intestinal gene expression profiling using exfoliated colonocytes: a pilot study. Biomarkers 8: 51-61, 2003.
32. Kawasaki A, Altieri DC, Lu C-D, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal carcinoma. Cancer Res 58: 5071-5074, 1998.
33. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T and Tanigawa N: Expression of survivin correlated with apoptosis proliferation and angiogenesis during human colorectal tumorigenesis. Cancer 91: 2026-2032, 2001.
34. Baldus SE, Zirbes TK, Engel S, Hanisch F-G, Monig SP, Lorenzen J, Glassmann J, Fromm S, Thiele J, Pichlamier H and Dienes H: Correlation of the immunohistochemical reactivity of muci peptide core MUC1 and MUC2 with the hisopathological subtype and prognosis of gastric carcinoma. Int J Cancer 79: 133-138, 1998.
35. Manne U, Weiss HL and Grizzle WE: Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. Clin Cancer Res 6: 4017-4025, 2000.
36. Yu H and Rohan T: Role of the insulin-like growth factor family in cancer development and progression. JNCI 92: 1472-1489, 2000.
37. Weber MM, Fothner C, Liu SB, Jung MC, Engelhardt D and Baretton GB: Overexpression of the insulin-like growth factor I receptor in human colon carcinoma. Cancer 95: 2086-2095, 2002.
38. Zhang L, Zhou W, Velcuescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B and Kinzler KW: Gene expression profiles in normal and cancer cells. Science 276: 1268-1272, 1997.
39. Hunt KJ, Toniolo P, Akhmedkhahov A, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E and Cacoks R: Insulin-like growth factor I and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prevent 11: 901-905, 2002.
40. Barozzi C, Ravaioli M, D'Errico A, Grazi GL, Poggioli G, Gavrini G, Mazziotti A and Grigioni WF: Relevance of biological markers in colorectal carcinoma. Cancer 94: 647-657, 2002.
41. Peters G, Gongoll S, Langer C, Mengel M, Piso P, Klempnauer J, Rüschoff J, Kreipe H and von Wasielewski R: IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive marker in colorectal cancer. Virchows Arch 443: 139-145, 2003.
42. Raju J, McCarthy B and Bird RP: Steady state levels of transforming growth factor-B1 and -B2 mRNA and protein expression are elevated in colonic tumors in vivo irrespective of dietary lipid intervention. Int J Cancer 100: 635-641, 2002.
43. Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JKV, Lu S, Nosrati A, Rerko RM, Swinler S, Beard L, Lutterbugh JD, Willis J, Platzer P and Markowitz S: PMEPA1, a transforming growth factor '-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res 63: 1568-1575, 2003.
44. Gong J, Ammanamanchi S, Ko TC and Brattain MG: Transforming growth factor '1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Cancer Res 63: 3340-3346, 2003.
45. Blobe G, Schiemann WP and Odish HF: Mechanisms of disease: role of transforming growth factor (beta) in human disease. N Engl J Med 342: 1350-1358, 2000.
46. Monteleone G, Kumberova A, Croft NM, McKenzie C, Sheer HW and MacDonald TT: Blocking Smad 7 TGF-[beta]1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601-609, 2001.
47. Doki Y, Imoto M, Han E K-H, Sgambuto A and Weinstein IB: Increased expression of the p27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1. Carcinogenesis 18: 1139-1148, 1997.
48. Moucadel V, Totaro M, Dell CD, Souberyan P, Dagorn JC, Freund JN and Iovanna JL: The homeobox gene cdx1 belongs to the p53-p21WAF-Bcl-2 network in intestinal epithelial cells. Biochem Biophys Res Commun 297: 607-615, 2002.
49. Bai YQ, Miyake S, Iwai T and Yuasa Y: cdx2, a homeobox transcription factor upregulates transcription of the p21/WAF1/CIP1 gene. Oncogene 22: 7942-7949, 2003.
50. Seoane J, Le HV and Massague J: Myc suppression of the p21(Cip1) cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729-734, 2002.
51. Backer S, Gelos M, Kobalz U, Hanski M-L, Böhm C, Mann B, Lövin N, Gratchev A, Mansmann U, Moyer MP, Riecken E-O and Hanski C: Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer 82: 868-874, 1999.
52. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretli G, Tomita N, Monden T, Rotterdam H and Weinstein IB: Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 58: 113-122, 1998.
53. Zhang H and Sun X-F: Loss of p27 expression predicts poor prognosis in patients with Dukes' B stage or proximal colorectal cancer. Int J Oncol 19: 49-52, 2001.
54. Liu DF, Ferguson K, Cooper GS, Grady WM and Willis J: p27 cell-cycle inhibitor is inversely correlated with lymph node metastasis in right-sided colon cancer. J Clin Lab Anal 13: 291-295, 1998.
55. Tanaka K, Ohtani M, Nohara T, Kawasaki H and Tanigawa N: Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinoma. Oncology 58: 45-51, 2000.
56. Loda M, Cakor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M: Increased proteasomedependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinoma. Nature Med 3: 231-234, 1997.
57. Noguchi T, Kikuchi R, Ono K, Takeno S, Moriyama H and Uchida Y: Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma. Onc Reports 10: 822-831, 2003.
58. Manne U, Jhala NC, Jones J, Weiss HL, Chatla C, Meleth S, Suarez-Cuerno C and Grizzle WE: Prognostic significance of p27KIP1 expression in colorectal adenocarcinoma is associated with tumor stage. Clin Cancer Res 10: 1743-1752, 2004.
59. Nagaoka S, Shiraishi J, Utsayama M, Seki S, Takemura T, Kitagawa M, Sawabe M, Takubo K and Hirokawa K: Prognosis of colorectal cancer in patients over 80 years old is associated with down regulation of the suppressor genes. J Clin Invest 37: 48-54, 2003.
60. Talamonti MS, Roh MS, Curley SA and Gallick GE: Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60, 1993.
61. Staley CA, Parikh NU and Gallick GE: Decreased tumorigenicity of human colon adenocarcinoma cell line by an antisense expression vector specific for c-src. Cell Growth Diff 8: 269-274, 1997
62. Malek RL, Irby RB, Guo QM, Lee K, Wong S, He M, Tsai J, Frank B, Liu ET, Quackenbush J, Jore R, Yeatman TJ and Lee NH: Identification of Src transformation fingerprint in human colon cancer. Oncogene 21: 7256-7265, 2002
63. Allgayer H: Molecular regulation of urokinase-receptor gene expression as one potential concept for molecular staging and therapy. Rec Results Cancer Res 162: 15-30, 2003.
64. Duffy MJ: The urokinase plasminogen activator system: role in malignancy. Curr Pharmaceut Des 10: 39-49, 2004.
65. Fuchs T and Allgayer H: Transcriptional regulation of the urokinase receptor (u-PAR) - a central molecule of invasion and metastasis. Biolog Chem 384: 755-761, 2003.
66. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
67. Carmeliet P, Moons L, Lijuen R, Baes M, Lemaitue V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupus F and Collen S: Urokinase-generated plasmin activates matrix metalloproteinase during aneurysm formation. Nature Gen 17: 439-444, 1997.
68. Rifkin DB: Cross-talk among proteases and matrix in the control of growth function. Fibrinol Proteolysis 11: 3-9, 1997.
69. Gum R, Juarez J, Allgayer H, Mazar A, Wang P and Boyd D: Stimulation of the urokinase-type plasminogen activator receptor expression by PMA requires a JNK1-dependent signaling module. Oncogene 17: 213-225, 1998.
70. Allgayer H, Wang H, Shirasawa S, Sasazuki T and Boyd DD: Targeted disruption of k-ras oncogene in an invasive cancer cell line down-regulates urokinase receptor expression and plasminogendependent proteolysis. Br J Cancer 80: 1884-1891, 1999.
71. Pories SE, Hess DT, Swenson K, Lotz M, Moussa R, Steels G, Shibata D, Rieger-Christ KM and Summerhayes C: Overexpression of pp60c-src elicits invasive behavior in rat colon epithelial cells. Gastroenterology 114: 1335-1338, 1998.
72. Wang Y, Dang J, Wang H, Allgayer H, Murrel GAC and Boyd D: Identification of a novel nuclear factor-kappa B sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem 267: 3248-3254, 2000.
73. Hapke S, Gawaz M, Dehne K, Köhler J, Marshall JF, Graeff H, Schmitt M, Reuning U and Lengyel E: '3A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol 6: 2118-2132, 2001.
74. Leupold JH, Colburn NH, Yang H, Lengyel E, Schildberg FW, Heiss MM and Allgayer H: First evidence for the new tumor suppressor Pdcd4 as a regulator of u-PAR, an invasion-related gene. Proc Am Soc Cancer Res 43: 622, 2002.
75. Nelson A, Fingleton, Rothenberg ML and Matrisian LM: Matrix metalloproteinase: biological activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
76. Sardinha TC, Nogures JJ, Xiong H, Weiss EG, Wexner SD and Abramson S: Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer. Dis Colon Rectum 43: 389-395, 2000.
77. Murray GI, Duncan ME, O'Neil P, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461-462, 1996.
78. Malhotra S, Newman E, Eisenberg D, Scholes J, Wieczorek R, Mignatti P and Shamamian P: Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer. A possible mechanism of neoplastic progression. Dis Colon Rectum 45: 537-543, 2002.
79. Baba K, Kusumoto H, Horaguchi M, Ueo H and Akiyoshi T: Analysis of MT1-MMP and MMP2 expression in human gastric cancer. Int J Cancer 74: 316-321, 1997.
80. Mori M, Barnard G.F, Mimori K, Ueo H, Akiyoshi T and Sugimuchi K: Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinoma. Cancer 75: 1516-1519, 1995.
81. Ichikawa Y, Ishikawa T and Momiyama N: Detection of regional lymph node metastases in colon cancer by using RPPCR for matrix metalloproteinase-7, matrilysin. Clin Exp Metastasis 16: 3-8, 1998.
82. Yamamoto H, Adachi Y and Itoh F: Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 59: 3313-3316, 1999.
83. Notterman DA, Alon U, Sierk AJ and Levine AJ: Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide array. Cancer Res 61: 3124-3130, 2001.
84. Matsuyama Y, Takao S and Aikou T: Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 80: 105-110, 2002.
85. Brabletz T, Jung A, Dag S and Kirchner T: Beta-catenin induces invasive growth by activating matrix metalloproteinases in colorectal carcinoma. Verhandle Deutsch Gesellschaft Pathologie 84: 175-181, 2000.
86. Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A and Atomi Y: Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 84: 1317-1321, 2001.
87. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y and Imai K: Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 45: 252-258, 1999.
88. Oberg A, Hoyhtya M, Tavelin B, Stenling R and Lindmark G: Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 20: 1085-1091, 2000.
89. Herrlich P, Pals S and Ponta H: CD44 in colon cancer. Eur J Cancer 31A: 1110-1112, 1995.
90. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Madruga MH, Lanham IS, Joynes CJ, Vo KT, Guha A, Matsumoto M, Ushio Y, Saya H and Wong AJ: Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160: 441-447, 2002.
91. Wong K, Rubenthiran U and Jothy S: Motility of colon cancer cells: modulation by CD44 isoform expression. Exp Mol Pathol 75: 124-130, 2003.
92. Kuniyasu H, Chihara Y, Kubozoe T and Takahashi T: Coexpression of CD44v3 and heparanase is correlated with metastasis of human colon cancer. Int J Mol Med 10: 333-337, 2002.
93. Coppola D, Hyacinthe M and Fu L: CD44v6 expression in human colorectal carcinoma. Hum Pathol 29: 627-635, 1998.
94. Nihei Z, Ichikawa W and Kojima K: The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surg Today 26: 760-761, 1996.
95. Finke LH, Zorb C and Haensch W: Expression of CD44 isoforms-a new histopathologic parameter in colorectal carcinoma? Zentralbl Chir 121: 450-454, 1996.
96. Yamaguchi A, Urano T and Goi T: Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 14: 1122-1127, 1996.
97. Ropponen K, Tammi M and Parkinen J: Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer. Cancer Res 58: 342-347, 1998.
98. Imazeki F, Yokosuka O, Yamaguchi T, Ohto M, Isono K and Omata M: Expression of variant DC44 messenger RNA in colorectal aenocarcinoma and adenomatous polyps in humans. Gastroenterology 110: 362-368, 1996.
99. Gotley DC, Fawcett J, Walsh MD, Roeder JA, Simmons DL and Antalis TM: Alternatively spliced variety of the cell adhesion molecule CD44 and tumor progression in colorectal carcinoma. Br J Cancer 74: 342-351, 1996.
100. Fisher LW, Torchia DA, Fohr B, Young MF and Fedarko NS: The solution structures of two SIBLING proteins, bone sialoprotein and osteoprotein by NMR. Biochem Biophys Res Commun 280: 460-465, 2001.
101. Yeatman TJ and Chambers AF: Osteopontin and colon cancer progression. Clin Exp Metastasis 20: 85-90, 2003.
102. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM and Chambers AF: Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18: 4237-4246, 1999.
103. Lecrone V, Li W, Devoll RE, Logothetis C and Farch-Carson MC: Calcium signals in prostate cancer cells: specific activity by bone matrix proteins. Cell Calcium 27: 35-42, 2000.
104. Fedarko NS, Jain A, Karadag A, Van Eman MR and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon breast, prostate, and lung cancer. Cancer Res 7: 4060-4066, 2001.
105. Senger DR, Peruzzi CA and Papadopoulos A: Elevated expression of selected phosphoprotein I (osteoprotein, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9: 1291-1299, 1989.
106. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K and Peruzzi CA: Osteopontin expression and distribution in human carcinoma. Am J Pathol 145: 610-623, 1994.
107. Agrawal LD, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D and Yeatman TJ: Osteopontin identified as lead marker of colon cancer progression using pooled sample expression profiling. JNCI 94: 513-521, 2002.
108. Ramaswamy S, Ross KN, Lander ES and Golub TR: A molecular signature in primary solid tumors. Nature Genet 33: 49-54, 2003.
109. DeMuth JP, Jackson CM, Weaver DA, Crawford EL, Durzinsky DS, Durham SJ, Zaher A, Phillips ER, Khuder SA and Willey JC: The gene expression index cmyc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. Am J Respir Cell Mol Biol 19: 18-29, 1998.